$3.40
0.87% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US92915B1061
Symbol
VYGR
Sector
Industry

Voyager Therapeutics, Inc. Stock price

$3.40
+0.19 5.92% 1M
-1.96 36.57% 6M
-2.27 40.04% YTD
-5.05 59.76% 1Y
-2.96 46.54% 3Y
-9.50 73.64% 5Y
-14.35 80.85% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.03 0.87%
ISIN
US92915B1061
Symbol
VYGR
Sector
Industry

Key metrics

Market capitalization $188.14m
Enterprise Value $-5.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.05
EV/Sales (TTM) EV/Sales -0.09
P/S ratio (TTM) P/S ratio 2.81
P/B ratio (TTM) P/B ratio 0.69
Revenue growth (TTM) Revenue growth -43.75%
Revenue (TTM) Revenue $66.96m
EBIT (operating result TTM) EBIT $-101.80m
Free Cash Flow (TTM) Free Cash Flow $-114.01m
Cash position $236.02m
EPS (TTM) EPS $-1.46
P/E forward negative
P/S forward 4.16
EV/Sales forward negative
Short interest 6.25%
Show more

Is Voyager Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Voyager Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Voyager Therapeutics, Inc. forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Voyager Therapeutics, Inc. forecast:

Buy
100%

Financial data from Voyager Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
67 67
44% 44%
100%
- Direct Costs 4.55 4.55
0% 0%
7%
62 62
45% 45%
93%
- Selling and Administrative Expenses 32 32
5% 5%
48%
- Research and Development Expense 127 127
32% 32%
190%
-97 -97
679% 679%
-145%
- Depreciation and Amortization 4.55 4.55
0% 0%
7%
EBIT (Operating Income) EBIT -102 -102
497% 497%
-152%
Net Profit -85 -85
2,686% 2,686%
-126%

In millions USD.

Don't miss a Thing! We will send you all news about Voyager Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Voyager Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled “Highly...
Neutral
GlobeNewsWire
14 days ago
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg –
Neutral
GlobeNewsWire
22 days ago
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg -
More Voyager Therapeutics, Inc. News

Company Profile

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alfred Sandrock
Employees 172
Founded 2013
Website www.voyagertherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today